Sumanta K. Pal and Robert A. Figlin Ramucirumab in metastatic renal cell carcinoma: The beginning or the end? Cancer 120
The current editorial focuses on a phase 2 study evaluating ramucirumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior sunitinib and/or sorafenib therapy. The potential for further development is discussed in the context of the rapidly changing landscape of therapy for mRCC.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf